Sucralose, Stevia, Gut Microbiome and Glucose Metabolism
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02800707|
Recruitment Status : Completed
First Posted : June 15, 2016
Last Update Posted : March 22, 2018
|Condition or disease||Intervention/treatment||Phase|
|Impaired Glucose Tolerance||Other: Sucralose Other: Stevia||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Primary Purpose:||Basic Science|
|Official Title:||Sucralose, Stevia, Gut Microbiome and Glucose Metabolism|
|Actual Study Start Date :||January 3, 2017|
|Actual Primary Completion Date :||January 31, 2018|
|Actual Study Completion Date :||January 31, 2018|
Active Comparator: Sucralose
Participants will be asked to consume 180 mg/day of sucralose (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 340 mg/day of sucralose (or 5.5 12-oz cans of sucralose-sweetened diet soda).
Active Comparator: Stevia
Participants will be asked to consume 180 mg/day of stevia (in the form of capsules which is equivalent to three 12-oz cans of diet soda) for 14 days. According to the FDA, a 150 lb. person may consume up to 800 mg/day of stevia (or about 12 cans of stevia-sweetened diet soda).
- 2-hour glucose [ Time Frame: 14 days ]An oral glucose tolerance test will be administered before and after consuming assigned sweetener to determine change in 2-hour glucose
- Gut microbiome [ Time Frame: 14 days ]Gut microbiota will be measured before and after consuming assigned sweetener to determine change in gut microbiota.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02800707
|United States, Minnesota|
|Minneapolis, Minnesota, United States, 55454|
|Principal Investigator:||Lyn M Steffen, PhD||University of Minnesota|